Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped up prior to trading on Monday . The stock had previously closed at $4.97, but opened at $5.18. Inventiva shares last traded at $5.1250, with a volume of 16,606 shares trading hands.

Analyst Ratings Changes

IVA has been the subject of several research reports. Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. HC Wainwright set a $24.00 target price on Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. Truist Financial assumed coverage on shares of Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective for the company. Barclays assumed coverage on shares of Inventiva in a report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Inventiva presently has an average rating of “Buy” and an average target price of $16.56.

Inventiva Trading Down 0.4%

The business’s fifty day moving average price is $5.77 and its 200-day moving average price is $5.34.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. Sell-side analysts anticipate that Inventiva S.A. Sponsored ADR will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in Inventiva during the second quarter worth about $32,000. Virtu Financial LLC bought a new stake in shares of Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd purchased a new position in shares of Inventiva in the 4th quarter worth about $84,000. NewEdge Advisors LLC purchased a new position in shares of Inventiva in the 3rd quarter worth about $116,000. Finally, Cerity Partners LLC purchased a new position in shares of Inventiva in the 4th quarter worth about $93,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.